A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Clinical trial NCT07556549 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07556549
- Sponsor
- Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-05-18
- Primary completion
- 2026-08-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.